McFarland Laboratory
700 Planetarium Place 76019 Wolfville, NS, Canada

More exciting November news! We are excited that our TLD-1433 has been granted FDA fast track status! "The accelerated communication with the FDA potentially allows, TLD-1433, in combination with the TLC-3200 medical laser system (TLC-3200), to be the first intravesical patient-specific Ruthenium-based PDC for the treatment of patients with BCG-Unresponsive NMIBC CIS, with or without papillary Ta or T1 tumours."

Some November updates: Theralase Technologies (Toronto, Canada), is currently underway with their lead compound, TLD-1433 (invented in McFarland Labs), into Phase II Non Muscle Invasive Bladder Cancer (NMIBC) clinical study for Bacillus Calmette-Guérin (BCG)-unresponsive patients at 4 Canadian clinical study sites. But here is even more exciting news!!! TLD-1433 has now shown remarkable high-kill rate in a preclinical analysis of Coronavirus BSL-2!! (note: this is not Covid-19 strain which is caused by BSL-3 virus). https://theralase.com/theralase-technology-demonstrates-hi/

We are also on Twitter! @McFarland_Labs https://twitter.com/McFarland_Labs

Another new journal article, a collaboration between the McFarland lab and Dr. Allison Thompson group at Dalhousie University! https://pubs.rsc.org//conte/articlepdf/2020/SC/D0SC04500D

Ongoing news from our lab! https://www.theshorthorn.com//article_ad47c458-f89f-11ea-9